Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.40 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.39 |
| ▸ | ROCK2 known ✓ | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.39 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.39 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047171 | 0.81 | PTPN2 (0.58) | NPSR1LMNAALDH1A1CYP17A1RAB9A | |
| SCHEMBL14837761 | 0.79 | CYP17A1 (0.49) | CYP17A1CYP26A1TSHRRAB9AKDM4E | |
| SCHEMBL4047174 | 0.77 | LMNA (0.41) | NPSR1LMNAALDH1A1CYP17A1CYP26A1 | |
| Hydrochloric Acid SCHEMBL23246054 | 0.76 | NPSR1 (0.80) | NPSR1LMNAALDH1A1F2F7 | |
| SCHEMBL5566007 | 0.74 | CYP17A1 (0.43) | CYP17A1CYP26A1KDM4E | |
| SCHEMBL13720325 | 0.73 | KDM4E (0.54) | ALDH1A1CYP17A1CYP26A1HPGDRAB9A | |
| SCHEMBL27023069 | 0.71 | KMT2A (0.61) | NPSR1LMNAALDH1A1F2F7 | |
| Hydrochloric Acid SCHEMBL27414471 | 0.71 | ROCK2 (0.60) | LMNAFLT3TSHRULK1GLA | |
| SCHEMBL13144615 | 0.70 | ALDH1A1 (0.58) | NPSR1LMNAALDH1A1FLT3DHODH | |
| SCHEMBL1553389 | 0.70 | ROCK2 (0.61) | LMNAFLT3HPGDTSHRULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579352-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | MABIRE DOMINIQUE | 2008-03-06 | — | — | US | disclosed |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | disclosed |
| US-7179825-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-6936626-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-30 | — | — | US | disclosed |
| US-20050165018-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1037880-B1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | disclosed |
| US-20020115653-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6319939-B1 | P-(HETEROCYCLIC METHYL)-SUBSTUTED ANILIDES ARE POTENT INHIBITORS OF THE RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-11-20 | — | — | US | disclosed |
| EP-1037880-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029674-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115653-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | FLT3 1458/4885GLA 2176/4885ROCK2 2016/4885 |
| US-20050165018-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | FLT3 1229/4885GLA 2520/4885ROCK2 2868/4885 |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | RXRA, RXRB, RXRG | FLT3 1144/4885GLA 2448/4885ROCK2 2677/4885 |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | FLT3 1229/4885GLA 2520/4885ROCK2 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.